KIORA PHARMACEUTICALS INCKPRXEarnings & Financial Report
Nasdaq · Health Care · Pharmaceutical Preparations
Kiora Pharmaceuticals Inc. is a clinical-stage biotechnology company focused on developing innovative therapies for ophthalmic diseases, including retinal disorders, uveitis, and other conditions with high unmet medical needs. It operates in the global biopharmaceutical market, targeting patient populations with limited existing treatment options.
Top Holders
| Holder | % Owned | Shares | Change | As of |
|---|---|---|---|---|
| Lincoln Park Capital Fund, LLC | 9.99% | 768.2K | — | 2024-02-14 |
| ADAR1 Capital Management, LLC | 9.99% | 310.8K | — | 2024-11-14 |
| Stonepine Capital Management, LLC | 9.99% | 307.2K | flat | 2024-11-13 |
| s. AIGH Capital Management, LLC | 9.90% | 2.3M | — | 2024-02-07 |
| Alyeska Investment Group, L.P. | 8.40% | 256.4K | — | 2024-11-14 |
| THE GOLDMAN SACHS GROUP, INC. | 6.10% | 180.8K | — | 2024-11-12 |
| Nos. of above persons | 3.50% | 109.2K | ▼ -6.40pp | 2024-11-14 |
| Mitchell | 1.50% | 117.1K | — | 2024-02-06 |
Insider Transactions
Net 90d: +$0 · buys $0 / sells $0Range:
Action:
Role:
| Insider | Role | Action | ||||
|---|---|---|---|---|---|---|
| 2026-03-06 | Melissa Tosca | CFO | Grant | 6.5K | $0.00 | $0 |
| 2026-03-06 | Strem Brian M. | President and CEO | Grant | 16.7K | $0.00 | $0 |
| 2026-03-06 | Daniels Eric Joseph | Chief Development Officer | Grant | 6.5K | $0.00 | $0 |
1–3 of 3